Evidence map›Paper›PMID 25307297›Full record

Trial reportCNS neuroscience & therapeutics2014

Recurrent stroke was associated with poor quality of life in patients with transient ischemic attack or minor stroke: finding from the CHANCE trial.

Yi-Long Wang, Yue-Song Pan, Xing-Quan Zhao, David Wang, S Claiborne Johnston, Li-Ping Liu, Xia Meng, An-Xin Wang, Chun-Xue Wang, Yong-Jun Wang and 1 more

2 registry-linked trialsAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in CNS neuroscience & therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 45 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03507374 early_phase1terminatedstarted 2018, after this paper: background citation

PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis

Ran2018Enrolled20Registered outcomes5Posted comparisons0ConditionsIntracranial Atherosclerosis, Intraplaque Hemorrhage, StrokeArmsAlirocumab, Placebo
PMID 26783308PMID 15800226PMID 16239630PMID 16439704PMID 17312027PMID 19807851PMID 21164126PMID 21536995PMID 21958949PMID 22872053PMID 23404720PMID 23463579other papers from this trial
Open the trial in the graph
NCT05907629 recruitingnot on this mapstarted 2024, after this paper: background citation

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging

TypeobservationalSponsorYale UniversityRan2024 to 2029Enrolled300ConditionsStroke, Intracranial Atherosclerotic Stenosis (ICAS)ArmsMRI
3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yi-Long WangDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; China National Clinical Research Center for Neurological Diseases (NCRC-ND), Beijing, China.
Yue-Song Pan
Xing-Quan Zhao
David Wang
S Claiborne Johnston
Li-Ping Liu
Xia Meng
An-Xin Wang
Chun-Xue Wang
Yong-Jun Wang
CHANCE investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo examine the health-related quality of life (HRQOL) in patients with transient ischemic attack (TIA) or minor stroke and assess the impact of recurrent stroke on HRQOL.

methodsHealth-related quality of life data on patients participated in the Clopidogrel in High-risk patients with Acute Nondisabling Cerebrovascular Events (CHANCE) trial were analyzed. The available 90-day EuroQoL data (EQ-5D) were used to calculate EQ-5D index score. Poor HRQOL was defined as an EQ-5D index score ≤0.5. The characteristics of HRQOL and factors predicting poor HRQOL in these patients were then explored.

resultsAmong the total 5170 patients enrolled, 90-day HRQOL data were obtained from 5104 patients for analysis. The mean EQ-5D index score at day 90 was 0.88 ± 0.21 for all patients, but only 0.42 ± 0.35 for those with recurrent strokes. Poor 90-day HRQOL was found in 294 (5.8%) patients. Patients with poor HRQOL had more strokes during follow-up than patients with good HRQOL (94.9 vs. 4.7%, P < 0.001). Age, history of hypertension and diabetes, and NIHSS at baseline were independent risk factors for predicting poor HRQOL. Stroke recurrence, NIHSS at baseline, age, and minor stroke on admission became independent risk factors once stroke recurrence was added into the model.

conclusionsStroke recurrence was associated with poor HRQOL in patients with TIA or minor strokes. Interventions focusing on controlling risk factors and prevention of worsening of neurological function may prevent poor HRQOL in these patients.

Indexed as

Treatment OutcomeAgedDouble-Blind MethodFemaleFollow-Up StudiesHumansIschemic Attack, TransientMaleMiddle AgedQuality of LifeRecurrenceRetrospective StudiesRisk FactorsStrokeEQ-5DHealth outcomesQuality of lifeStrokeTransient ischemic attack

Identifiers

PMID25307297
PMCPMC6493002

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.